Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients.
(2011) Clinical Biochemistry — Vol. 44, n° 13, p. 1062-1066 (2011)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 262.08 KB
Details
- Authors
- Abstract
- TPMT deficiency is associated with azathioprine (AZA)-induced myelosuppression (MS). However, in one previous study, only about ¼ of MS episodes in Crohn's Disease patients under AZA can be attributed to TPMT deficiency. Recently, new TPMT mutations have been described and our aim is to investigate their clinical relevance before and after a first MS episode on thiopurine therapy.
- Affiliations
Citations
Dewit, O., Moreels, T., Baert, F., Peeters, H., Reenaers, C., de Vos, M., Van Hootegem, Ph., Muls, V., Veereman, G., Mana, F., Van Outryve, M., Holvoet, J., Naegels, S., Piessevaux, H., Horsmans, Y., & Gala, J.-L. (2011). Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. Clinical Biochemistry, 44(13), 1062-1066. https://doi.org/10.1016/j.clinbiochem.2011.06.079 (Original work published 2011)